300254.SZ深圳证券交易所 · 创业板 ChiNext
Shanxi C&Y Pharmaceutical Group 仟源医药
Chemical Pharmaceuticals 化学制药
¥8.85−¥0.14 · −1.56%
Open 开盘
¥9.00
High 最高
¥9.07
Low 最低
¥8.79
Prev Close 昨收
¥8.99
Volume 成交量
583.7万股
Turnover 成交额
¥5,187.2万
Mkt Cap 总市值
¥23亿
P/E 市盈率
79.2×
Recent Activity 近期动态All Filings 全部公告 →
22 significant filings since 30 May 2026: 20 on equity incentive, 1 on buyback and 1 on change of interest. The latest, on 24 Sep 2026: 关于2025年限制性股票激励计划第一个解除限售期解除限售股份上市流通提示性公告.
自 30 May 2026 起有 22 份重大公告：equity incentive 20 份、buyback 1 份、change of interest 1 份。最新一份（24 Sep 2026）：关于2025年限制性股票激励计划第一个解除限售期解除限售股份上市流通提示性公告。
8.009.0010.0011.0012.0013.0014.00
Volume 成交量
5,197.6万
Sep 25Dec 25Mar 26Jun 26Sep 26
Overview 概览Deep Report 深度报告Financials 财务Valuation 估值Ownership 股东Analysts 券商Estimates 预测News 动态Events 事件Peers 同业
Relative Value 同业比较
Chemical Pharmaceuticals 化学制药 · 158 listed peers
| Measure 指标 | This Company 本公司 | Peer Median 同业中值 | Standing 排位 | |
|---|---|---|---|---|
| Market Cap 市值 | ¥23亿 | ¥63亿 | 16th lowest of 158 · 158 家中第 16 低 | |
| Trailing P/E 市盈率 | 79.2x | 38.6x | 27th highest of 112 · 112 家中第 27 高 | |
| P/B 市净率 | 5.1x | 2.5x | 35th highest of 157 · 157 家中第 35 高 | |
| Revenue Growth 营收增速 | -5.7% | 1.6% | 53rd lowest of 156 · 156 家中第 53 低 | |
| Profit Growth 净利增速 | 1,025.3% | 1.9% | 4th highest of 158 · 158 家中第 4 高 | |
| Gross Margin 毛利率 | 66.4% | 50.2% | 40th highest of 155 · 155 家中第 40 高 | |
| Net Margin 净利率 | 3.3% | 9.8% | 46th lowest of 157 · 157 家中第 46 低 | |
| Return on Equity 净资产收益率 | 1.1% | 3.1% | 47th lowest of 157 · 157 家中第 47 低 | |
| Debt to Assets 资产负债率 | 65.5% | 28.0% | 14th highest of 158 · 158 家中第 14 高 | |
| Grade Score 评级得分 | 48 | 51 | 72nd lowest of 157 · 157 家中第 72 低 |
Statement figures are for the period to 30 Jun 2026, filed by 158 of 158 peers. A rank needs 5 or more peers with a value. A company with no earnings has no P/E. 报表数据为截至 30 Jun 2026 的期间，158 家同业中 158 家已披露。排位至少需要 5 家有数据的同业；无盈利的公司没有市盈率。
Largest Peers 主要同业
| Peer 同业 | Market Cap | P/E | P/B | Revenue Growth | Net Margin | ROE | Grade |
|---|---|---|---|---|---|---|---|
| Beone Medicines 百济神州 | ¥3,979亿 | 92.9x | 11.2x | 26.8% | 14.7% | 9.9% | B |
| Hengrui Pharma 恒瑞医药 | ¥2,977亿 | 38.5x | 4.6x | -1.9% | 28.9% | 8.0% | C |
| Haisco Pharmaceutical Group 海思科 | ¥699亿 | 73.7x | 14.3x | 54.7% | 27.5% | 18.3% | B |
| CSPC Innovation Pharmaceutical 石药创新 | ¥620亿 | 60.6x | 15.8x | 208.7% | 47.9% | 38.2% | B |
| Sichuan Kelun Pharmaceutical 科伦药业 | ¥618亿 | 33.8x | 2.5x | -2.7% | 16.1% | 4.6% | C |
| Fosun Pharma 复星医药 | ¥610亿 | 18.0x | 1.3x | 4.8% | 10.5% | 3.5% | D |
| Innocare 诺诚健华 | ¥528亿 | 57.5x | 6.9x | 55.5% | 21.1% | 3.2% | C |
| Allist 艾力斯 | ¥469亿 | 17.5x | 5.5x | 39.9% | 46.4% | 19.7% | B |
| Huadong Medicine 华东医药 | ¥457亿 | 13.2x | 1.8x | 1.8% | 8.3% | 7.3% | C |
| Shenzhen Salubris Pharmaceuticals 信立泰 | ¥337亿 | 50.0x | 3.9x | 16.3% | 15.8% | 4.3% | C |
| Humanwell Healthcare ST人福 | ¥307亿 | 15.1x | 1.6x | -0.0% | 14.0% | 6.8% | C |
| Apeloa Pharmaceutical 普洛药业 | ¥293亿 | 34.5x | 4.5x | -11.4% | 10.8% | 8.1% | D |
| Zelgen 泽璟制药 | ¥288亿 | 52.5x | 16.8x | 220.9% | 53.1% | 45.7% | B |
| Dizal Pharmaceutical 迪哲医药 | ¥263亿 | — | 23.2x | 47.2% | -40.8% | -17.2% | D |
| Shanxi C&Y Pharmaceutical Group 仟源医药 | ¥23亿 | 79.2x | 5.1x | -5.7% | 3.3% | 1.1% | D |
Peers are listed by market cap, with this company highlighted. 同业按市值排列，本公司高亮显示。